Treatment with the Probiotic Product Aviguard<sup>®</sup> Alleviates Inflammatory Responses during <i>Campylobacter jejuni</i>-Induced Acute Enterocolitis in Mice
Prevalences of <i>Campylobacter (C.) jejuni</i> infections are progressively rising globally. Given that probiotic feed additives, such as the commercial product Aviguard<sup>®</sup>, have been shown to be effective in reducing enteropathogens, such as <i>Salmonella<...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/13/6683 |
| Summary: | Prevalences of <i>Campylobacter (C.) jejuni</i> infections are progressively rising globally. Given that probiotic feed additives, such as the commercial product Aviguard<sup>®</sup>, have been shown to be effective in reducing enteropathogens, such as <i>Salmonella</i>, in vertebrates, including livestock, we assessed potential anti-pathogenic and immune-modulatory properties of Aviguard<sup>®</sup> during acute <i>C. jejuni</i>-induced murine enterocolitis. Therefore, microbiota-depleted IL-10<sup>−/−</sup> mice were infected with <i>C. jejuni</i> strain 81-176 by gavage and orally treated with Aviguard<sup>®</sup> or placebo from day 2 to 4 post-infection. The applied probiotic bacteria could be rescued from the intestinal tract of treated mice, but with lower obligate anaerobic bacterial counts in <i>C. jejuni</i>-infected as compared to non-infected mice. Whereas comparable gastrointestinal pathogen loads could be detected in both groups until day 6 post-infection, Aviguard<sup>®</sup> treatment resulted in improved clinical outcome and attenuated apoptotic cell responses in infected large intestines during acute campylobacteriosis. Furthermore, less distinct pro-inflammatory immune responses could be observed not only in the intestinal tract, but also in extra-intestinal compartments on day 6 post-infection. In conclusion, we show here for the first time that Aviguard<sup>®</sup> exerts potent disease-alleviating effects in acute <i>C. jejuni</i>-induced murine enterocolitis and might be a promising probiotic treatment option for severe campylobacteriosis in humans. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |